Assessment of Simplified Methods for Quantification of 18 F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer.

Autor: Kramer GM; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands ge.kramer@vumc.nl., Yaqub M; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Vargas HA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Schuit RC; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Windhorst AD; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., van den Eertwegh AJM; Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., van der Veldt AAM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Departments of Medical Oncology, Radiology, and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands., Bergman AM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Burnazi EM; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Lewis JS; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Radiology, Weill Cornell Medicine, New York, New York., Chua S; Department of Nuclear Medicine, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom., Staton KD; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Beattie BJ; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York., Humm JL; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York., Davis ID; Monash University and Eastern Health, Eastern Health Clinical School, Box Hill, Australia., Weickhardt AJ; Department of Medical Oncology, Olivia Newton-John Cancer Research Institute, Austin Hospital, Melbourne, Victoria, Australia., Scott AM; Department of Medical Oncology, Olivia Newton-John Cancer Research Institute, Austin Hospital, Melbourne, Victoria, Australia.; Department of Molecular Imaging and Therapy, University of Melbourne, Heidelberg, Victoria, Australia., Morris MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; and.; Department of Medicine, Weill Cornell Medicine, New York, New York., Hoekstra OS; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Lammertsma AA; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Jazyk: angličtina
Zdroj: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2019 Sep; Vol. 60 (9), pp. 1221-1227. Date of Electronic Publication: 2019 Mar 08.
DOI: 10.2967/jnumed.118.220111
Abstrakt: 18 F-fluorodihydrotestosterone ( 18 F-FDHT) PET/CT potentially provides a noninvasive method for assessment of androgen receptor expression in patients with metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to assess simplified methods for quantifying 18 F-FDHT uptake in mCRPC patients and to assess effects of tumor perfusion on these 18 F-FDHT uptake metrics. Methods: Seventeen mCRPC patients were included in this prospective observational multicenter study. Test and retest 30-min dynamic 18 F-FDHT PET/CT scans with venous blood sampling were performed in 14 patients. In addition, arterial blood sampling and dynamic 15 O-H 2 O scans were obtained in a subset of 6 patients. Several simplified methods were assessed: Patlak plots; SUV normalized to body weight (SUV BW ), lean body mass (SUV LBM ), whole blood (SUV WB ), parent plasma activity concentration (SUV PP ), area under the parent plasma curve (SUV AUC,PP ), and area under the whole-blood input curve (SUV AUC,WB ); and SUV BW corrected for sex hormone-binding globulin levels (SUV SHBG ). Results were correlated with parameters derived from full pharmacokinetic 18 F-FDHT and 15 O-H 2 O. Finally, the repeatability of individual quantitative uptake metrics was assessed. Results: Eighty-seven 18 F-FDHT-avid lesions were evaluated. 18 F-FDHT uptake was best described by an irreversible 2-tissue-compartment model. Replacing the continuous metabolite-corrected arterial plasma input function with an image-derived input function in combination with venous sample data provided similar K i results ( R 2 = 0.98). Patlak K i and SUV AUC,PP showed an excellent correlation ( R 2 > 0.9). SUV BW showed a moderate correlation to K i ( R 2 = 0.70, presumably due to fast 18 F-FDHT metabolism. When calculating SUV SHBG , correlation to K i improved ( R 2 = 0.88). The repeatability of full kinetic modeling parameters was inferior to that of simplified methods (repeatability coefficients > 36% vs. < 28%, respectively). 18 F-FDHT uptake showed minimal blood flow dependency. Conclusion: 18 F-FDHT kinetics in mCRPC patients are best described by an irreversible 2-tissue-compartment model with blood volume parameter. SUV AUC,PP showed a near-perfect correlation with the irreversible 2-tissue-compartment model analysis and can be used for accurate quantification of 18 F-FDHT uptake in whole-body PET/CT scans. In addition, SUV SHBG could potentially be used as an even simpler method to quantify 18 F-FDHT uptake when less complex scanning protocols and accuracy are required.
(© 2019 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze: MEDLINE
Externí odkaz: